MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

A

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

Search

Compugen Ltd

Abierto

1.7

Resumen

Variación precio

24h

Actual

Mínimo

1.67

Máximo

1.8

Métricas clave

By Trading Economics

Ingresos

-1.1M

-7.2M

Ventas

813K

2.3M

P/B

Media del Sector

60.333

50.291

BPA

-0.08

Margen de beneficio

-314.405

Empleados

74

EBITDA

-12M

-7.5M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+293.26% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-534M

152M

Apertura anterior

1.7

Cierre anterior

1.7

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Compugen Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

30 jun 2025, 21:26 UTC

Principales Movimientos del Mercado

AeroVironment Shares Slide on Stock, Notes Offerings

30 jun 2025, 16:50 UTC

Adquisiciones, fusiones, absorciones

BBVA Won't Withdraw Sabadell Offer

30 jun 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30 jun 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30 jun 2025, 23:38 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 jun 2025, 23:03 UTC

Ganancias

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30 jun 2025, 22:50 UTC

Adquisiciones, fusiones, absorciones

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30 jun 2025, 22:50 UTC

Ganancias

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30 jun 2025, 21:26 UTC

Ganancias

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30 jun 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

30 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 jun 2025, 19:46 UTC

Charlas de Mercado

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30 jun 2025, 19:16 UTC

Charlas de Mercado

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30 jun 2025, 19:10 UTC

Charlas de Mercado

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30 jun 2025, 19:07 UTC

Charlas de Mercado

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30 jun 2025, 18:27 UTC

Charlas de Mercado

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30 jun 2025, 17:08 UTC

Adquisiciones, fusiones, absorciones

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30 jun 2025, 17:00 UTC

Adquisiciones, fusiones, absorciones

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30 jun 2025, 16:41 UTC

Charlas de Mercado

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30 jun 2025, 16:32 UTC

Charlas de Mercado

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30 jun 2025, 16:23 UTC

Adquisiciones, fusiones, absorciones

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30 jun 2025, 16:22 UTC

Adquisiciones, fusiones, absorciones

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

30 jun 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

30 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

30 jun 2025, 16:07 UTC

Ganancias

Umicore to Post 1H Results on Aug 1

30 jun 2025, 15:59 UTC

Charlas de Mercado

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30 jun 2025, 15:55 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30 jun 2025, 15:54 UTC

Charlas de Mercado

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30 jun 2025, 15:41 UTC

Adquisiciones, fusiones, absorciones

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Comparación entre iguales

Cambio de precio

Compugen Ltd Esperado

Precio Objetivo

By TipRanks

293.26% repunte

Estimación a 12 meses

Media 7 USD  293.26%

Máximo 10 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.